MetaVia (MTVA) vs. Its Competitors Head to Head Review

MetaVia (NASDAQ:MTVA) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it weigh in compared to its competitors? We will compare MetaVia to related companies based on the strength of its valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Earnings & Valuation

This table compares MetaVia and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MetaVia	N/A	-$27.59 million	-0.91
MetaVia Competitors	$954.27 million	-$46.07 million	12.31

MetaVia’s competitors have higher revenue, but lower earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current recommendations and price targets for MetaVia and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1	0	2	0	2.33
MetaVia Competitors	5754	12164	37603	1166	2.60

MetaVia presently has a consensus price target of $7.50, suggesting a potential upside of 979.91%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 55.20%. Given MetaVia’s higher possible upside, equities analysts plainly believe MetaVia is more favorable than its competitors.

Risk & Volatility

MetaVia has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500. Comparatively, MetaVia’s competitors have a beta of 0.97, indicating that their average share price is 3% less volatile than the S&P 500.

Institutional & Insider Ownership

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 0.8% of MetaVia shares are owned by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares MetaVia and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-212.00%	-107.21%
MetaVia Competitors	-1,425.99%	-589.65%	-28.81%

Summary

MetaVia competitors beat MetaVia on 8 of the 13 factors compared.

MetaVia Company Profile

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.